Navigation Links
Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA

PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - Arrowhead Research Corporation (NASDAQ:ARWR) announced today that majority-owned subsidiary Calando Pharmaceuticals has published results in the Proceedings of the National Academy of Sciences (PNAS) of the first non-human primate study to use multiple, systemic dosing with Calando's lead siRNA therapeutic candidate.

Calando is using its proprietary technologies in targeted polymeric delivery systems and siRNA design to create new, targeted siRNA therapeutics. Its lead anti-cancer therapeutic candidate contains a linear cyclodextrin polymer, the siRNA, and a targeting agent. The formulation self assembles into nanoparticles that protect the siRNA from nuclease degradation in serum. One important result of the study was the lack of a significant immune response to the siRNA, demonstrating that the formulation is well tolerated at doses much higher than those previously shown to have anti-cancer effects. Calando is expecting to enter clinical trials with this formulation later this year.

Further information about Calando and the study can be found at www.calandopharma.com.

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ:ARWR) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.

About
'"/>




Page: 1 2 3

Related medicine technology :

1. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
2. Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
3. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
4. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
5. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
6. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
7. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Dec. 9, 2010 Customers using Elekta,s ... with seamless integration to Varian,s TrueBeam ™ ... to this linear accelerator is the most recent ... and the delivery systems of other cancer management ...
... Conn., Dec. 9, 2010 Boehringer Ingelheim Pharmaceuticals, Inc. ... the phase IIb/III LUX-Lung 1 trial show that afatinib ... 1.0 month for placebo) in progression-free survival (PFS) in ... to have an epidermal growth factor receptor (EGFR) mutation.(1) ...
Cached Medicine Technology:Cancer Treatment Centers' Oncology Information System Options Expand with New MOSAIQ Connectivity 2Cancer Treatment Centers' Oncology Information System Options Expand with New MOSAIQ Connectivity 3New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 2New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 3New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 4New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 5
(Date:4/17/2014)... in PLOS Pathogens , children who live in ... mount an immune response to infection with malaria parasites ... high fever and illness and partially control the growth ... help researchers develop future interventions that prevent or mitigate ... year, approximately 200 million cases of malaria occur worldwide, ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... team has created a new technology for modifying ... travel the body and selectively target cancer and ... devices that monitor and modify human physiology is ... no existing technology enabled bioengineers to build such ... respond in a customized fashion. , "The project ...
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
(Date:4/17/2014)... 17, 2014 By discovering a new mechanism that ... stroke, researchers at UC Irvine and the Salk Institute ... limit or prevent stroke-induced brain damage. , A complex ... of death and primary reason for disability in the ... stroke and lets blood-borne material into the brain, causing ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... recall as number of people sickened in outbreak rises to ... Jan. 14 (HealthDay News) -- A nationwide recall of peanut ... even as the number of people sickened by salmonella-contaminated peanut ... of America, based in Lynchburg, Va., issued the recall of ...
... effort by national SEIU officials to oust reformers, ... United Healthcare Workers (UHW) President Sal Rosselli and ... afternoon, according to UHW election committee chair Debby ... by national SEIU President Andy Stern to oust ...
... had fewer problems and a much higher quality of life ... three weeks after being discharged from hospital, according to research ... Nursing . , During the two-year study, researchers from Umea ... pedestrians who had attended the same emergency department after an ...
... Obesity continues to increase for women in the United ... ages of 35-44, there are approximately 3.3 million white ... who are obese. A new study published in the ... is an increased risk for midlife obesity among Mexican-American ...
... study from Indiana University suggests that even meager levels ... with serious mental illnesses (SMI) such as bipolar disorder, ... in the November issue of the " International Journal ... people with SMI demonstrate low levels of physical activity ...
... Jan. 14 Genworth Financial,s Long Term Care (LTC) ... the National LTC Network to sell Genworth,s long term ... National LTC Network will offer Genworth,s long term care ... will help expand Genworth,s distribution of its long term ...
Cached Medicine News:Health News:More Peanut Butter Recalled in Salmonella Outbreak 2Health News:More Peanut Butter Recalled in Salmonella Outbreak 3Health News:United Healthcare Workers Re-Elect All Statewide Officers 2Health News:Telephone support after traffic accidents reduces problems and improves quality of life 2Health News:Telephone support after traffic accidents reduces problems and improves quality of life 3Health News:Economic status affects obesity rates in Mexican-American and white women 2Health News:Physical activity, mood and serious mental illness 2Health News:Genworth Forges Strategic Relationship with National LTC Network 2
CCR Medical conventional laryngoscopes....
... Original LMA™ Airway., ,Launched in 1988, ... use is now standard practice in general ... worldwide the LMA Classic™ is a safe ... ,The LMA Classic™ can be used ...
... , ,Developed for cardiopulmonary resuscitation and ... LMA Fastrach™ has been designed to facilitate ... neck. The LMA Fastrach™ allows continuous ventilation ... emergency teams worldwide including NASA for its ...
... the production of airway management ... integrated solution to all your ... Portex Soft Seal Laryngeal Mask ... this wide portfolio of products ...
Medicine Products: